# Neuralink — Healthcare Investment Intelligence

> medical_device · Series E. MedFuel Intel profile as of 2026-06-12.

Neuralink is developing implantable brain-computer interfaces that translate neural signals into actions, with its website describing clinical trials in which people use Neuralink devices to control computers and robotic arms with their thoughts. The company was founded in 2016 and received FDA approval in 2023 to begin human trials, indicating it is a private, late-stage medical-device/neurotechnology company.

## Key facts (as of 2026-06-12)
- Sector: medical_device
- Stage: Series E
- Website: https://neuralink.com

## MedFuel assessment
- Intelligence score: 0/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/neuralink-44. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.